28 September 2010

Director's Share Transfer

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that David Davies, Director of Product Development, has today transferred 160,239 ordinary shares in the Company into his Hargreaves Lansdown Vantage SIPP account for no consideration.

There is no change in the beneficial ownership of these ordinary shares, and Mr Davies's holding in ordinary shares in the Company, as defined by the AIM Rules, remains unchanged as a result of the transfer at 532,572 ordinary shares, representing 0.79% of the Company's share capital.

 

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

© and Database Right: Futura Medical plc 2004 - 2013. All rights reserved.

Site map | Contact us | By using the website, you are deemed to have accepted the terms of the disclaimer.